CytoArt is pleased to welcome three recognized leaders in cell therapy and immuno-oncology to its Scientific Advisory Board.
The Scientific Advisory Board brings together expertise across CAR-T discovery, translational immunology, clinical development, and cell therapy commercialization. Their guidance will help CytoArt continue building practical research tools for CAR-T monitoring, anti-idiotype antibody development, VHH binder discovery, and related cell therapy applications.
As the CAR-T and cell therapy field continues to expand, reliable detection, characterization, and monitoring tools are becoming increasingly important across discovery, preclinical development, and translational research. CytoArt is grateful to work with advisors who understand these needs from scientific, clinical, and industry perspectives.
Scientific Advisory Board Members
Dr. Frederick Locke
Department Chair, Blood and Marrow Transplant and Cellular Immunotherapy
Program Lead, Blood and Marrow Transplant and Cellular Immunotherapy
Program Co-Leader, Immuno-Oncology
Moffitt Cancer Center
Dr. Locke brings strong clinical and translational leadership in CAR-T cell therapy, blood and marrow transplantation, and cellular immunotherapy. His experience in pivotal CAR-T clinical development provides valuable perspective on how cell therapy tools must support real translational and clinical needs.
Dr. Marco Ruella
Associate Professor of Medicine
Scientific Director, Lymphoma Program
Principal Investigator, Center for Cellular Immunotherapies
Director, CART Program, Penn Global Medicine
Cancer Co-Lead, Institute for Immunology and Immune Health
Full Member and COE Liaison, Abramson Cancer Center
University of Pennsylvania
Dr. Ruella brings deep academic and translational expertise in CAR-T cell therapy, lymphoma, leukemia, and mechanisms of resistance after cellular immunotherapy. His work has helped shape the understanding of how engineered T cell therapies can be designed, evaluated, and improved for patients with hematologic malignancies.
Dr. Michael Kalos
ImmunoScape, Board of Directors, Independent Member
Alloy Therapeutics, Inc., Executive Venture Partner
Next Pillar Consulting, LLC, Founder and Managing Director
Dr. Kalos brings extensive experience in T cell therapy, immuno-oncology, translational research, and biopharmaceutical strategy. His career has spanned academic translational laboratories, large pharmaceutical organizations, and biotech leadership roles, with broad experience advancing cell therapy programs from scientific concept toward clinical and commercial development.
Strengthening CytoArt's Cell Therapy Mission
CytoArt's mission is to support the cell therapy community with specialized reagents and technical solutions that make engineered immune cells easier to detect, measure, and understand.
With the guidance of its Scientific Advisory Board, CytoArt will continue advancing tools for CAR-T monitoring, anti-CAR antibody development, VHH binder discovery, and next-generation cell therapy research.
Learn more about CytoArt at www.cytoart.com.